Financial Performance - Total revenues for 2025 were $1,976,677, a decrease of 82.3% compared to $11,198,144 in 2024[404] - License revenue dropped to $1,500,000 in 2025 from $10,900,000 in 2024, reflecting a decline of 86.2%[404] - The operating loss for 2025 was $10,371,379, compared to an operating loss of $1,155,035 in 2024[404] - Net loss for 2025 was $9,627,505, contrasting with a net income of $8,352 in 2024[404] - Total revenue for 2025 was $1.98 million, a decrease of 82.4% from $11.20 million in 2024[417] - The company reported a net loss of $9.63 million for the year ended December 31, 2025, compared to a net income of $8,352 in 2024[407] - The Company reported a net loss of $9,627,505 for the year ended December 31, 2025, compared to a net income of $8,352 in 2024[449] - The net loss for the year ended December 31, 2025, was $9,627,505, compared to a net income of $8,352 in 2024[519] Cash and Assets - Cash and cash equivalents decreased to $5,205,842 as of December 31, 2025, down from $6,205,926 in 2024, a decline of 16.1%[402] - Total assets fell to $17,005,612 in 2025 from $22,510,501 in 2024, a decrease of 24.5%[402] - Total stockholders' equity decreased to $14,477,416 in 2025 from $20,997,565 in 2024, a decline of 30.9%[402] - Cash and cash equivalents at the end of 2025 were $5.21 million, down from $6.21 million at the end of 2024[411] - The Company had cash, cash equivalents, and marketable securities of approximately $14.9 million as of December 31, 2025[454] - The fair value of cash equivalents and government treasury bills was $14,184,232 as of December 31, 2025, down from $21,582,552 in 2024[441] Expenses - Research and development expenses increased to $8,583,919 in 2025, up from $7,351,753 in 2024, representing a rise of 16.7%[404] - Cash used in operating activities was $9.76 million in 2025, significantly higher than $1.22 million in 2024[407] - The Company incurred approximately $5.1 million in research and development expenses in 2025, up from $4.1 million in 2024[469] - Personnel costs increased to $4,031,626 in 2025 from $3,536,529 in 2024[519] - The Company’s rent expense was $376,000 for the year ended December 31, 2025, compared to $366,000 in 2024, reflecting a 3.7% increase[485] Stock and Equity - The company raised $2.87 million through the sale of common stock via an ATM offering in 2025, compared to $209,340 in 2024[407] - The Company issued 100,994 stock options in 2025 compared to 84,715 in 2024, and issued 0 restricted stock units in 2025 compared to 21,762 in 2024[431] - As of December 31, 2025, the Company has 417,309 outstanding stock options with a weighted average exercise price of $18.64 and a remaining contractual life of 6.70 years[505] - The Company has registered up to $50,000,000 of common shares for sale under the A.G.P. Sales Agreement, allowing for "at the market" offerings[493] - The Company has reduced the number of authorized shares of common stock from 200,000,000 to 75,000,000 as of June 4, 2025[489] - The Company’s stockholders approved an amendment to reduce the number of authorized shares, which became effective upon filing with the Secretary of State[489] - The Company’s stockholders approved a Rights Agreement that allows for the purchase of preferred stock under certain conditions, enhancing shareholder protection[498] Clinical and Product Development - The company has ongoing and planned clinical trials, with expectations for future product candidates and regulatory approvals[16] - The Company recognized 74.7% of its revenue from the Verity License agreement in 2025, amounting to $1.50 million[421] - The Company entered into the Verity License Agreement, granting GSL exclusive rights to commercialize TLANDO, with an initial license fee of $11.0 million, including payments of $2.5 million, $5.0 million, $2.5 million, and $1.0 million due by January 2026[458] - The Company recognized $1.0 million in licensing revenue and approximately $477,000 in sales-based royalty revenue under the Verity License Agreement during 2025[462] - The Company is eligible for development and sales milestone payments of up to $259.0 million based on sales achievements under the Verity License Agreement[459] - The Company entered into a Distribution and License Agreement with SPC Korea, receiving a one-time upfront fee and additional payments for marketing milestones, along with royalties on net sales in South Korea[463] - The Company has agreements with Pharmalink and Aché for TLANDO distribution in the GCC and Brazil, respectively, with both agreements including upfront fees and milestone payments[464][465] Tax and Deferred Assets - The income tax expense for 2025 was $200, a decrease from $681 in 2024, primarily due to changes in valuation allowance[474][475] - As of December 31, 2025, the Company had net deferred tax assets of $51.0 million, with a valuation allowance of the same amount, indicating uncertainty in realizing these benefits[477] - The Company has approximately $160.8 million in net operating loss carryforwards, with $46.5 million set to expire between 2025 and 2035[481] Miscellaneous - The Company operates as a single reporting segment focused on leveraging its proprietary drug delivery technology platform[517] - The common stock warrants from the February 2020 offering, which expired in February 2025, were classified as equity and no warrants were exercised during 2025[509] - The aggregate intrinsic value of outstanding stock options as of December 31, 2025, was $278,000, compared to approximately $29,000 as of December 31, 2024[507] - The company contributed $104,000 and $109,000 to the 401(k) Plan during the years ended December 31, 2025, and 2024, respectively[512] - The company sold 1,138,710 shares of common stock for net proceeds of $10.6 million under the A.G.P. Sales Agreement since December 31, 2025[526]

Lipocine (LPCN) shares soared 5.5% in the last trading session to close at $10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% gain over the past four weeks.Lipocine’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments of its investigational drug LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The company is evaluating the candidate in phase III stud ...

Financial Position - As of January 31, 2026, Lipocine Inc. had approximately $19 million in cash and cash equivalents[5] - The preliminary cash estimate is subject to completion of financial closing procedures and has not been audited[5] Clinical Trials - The company announced the last patient last visit (LPLV) in its pivotal Phase 3 clinical trial of LPCN for postpartum depression (PPD) on February 18, 2026[6]

SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the last patient has completed the final study visit (Last Patient Last Visit) in its Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). The randomized, double-blind, placebo-controlled study enrolled a total of 90 pa ...

Company Overview - Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company focused on developing oral, lipid-based hormone therapies for both men's and women's health, founded in 1997 and headquartered in Salt Lake City, Utah [5]. Clinical Development - On January 20, Lipocine Inc. announced the completion of enrollment and participant dosing in its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression. This milestone is significant as it reduces execution risk ahead of a key clinical readout expected to be reported in early Q2 2026 [4]. - The company anticipates topline safety and efficacy results for LPCN 1154 to be available early in the second quarter of 2026, as stated by CEO Mahesh Patel [4]. Market Potential - H.C. Wainwright raised its price target on Lipocine Inc. to $15 from $7, maintaining a Buy rating, citing the favorable safety profile of LPCN 1154 and the significant unmet need in postpartum depression. The firm views the program as a potential value driver as it progresses through late-stage development [2].

Core Viewpoint - Lipocine Inc. has completed enrollment and dosing in its Phase 3 clinical trial for LPCN 1154, an oral formulation of brexanolone aimed at treating postpartum depression (PPD) [1][2]. Group 1: Clinical Trial Details - The Phase 3 study involved 90 patients randomized to receive either LPCN 1154 or a placebo, demonstrating a favorable safety profile with no serious adverse events reported [2][3]. - The trial is designed as a pivotal, randomized, double-blind study for women aged 15 and older diagnosed with severe PPD, conducted entirely in an outpatient setting [3]. - Topline safety and efficacy results are expected to be reported in early Q2 2026, which will support a 505(b)(2) NDA submission for LPCN 1154 [2][3]. Group 2: Product Information - LPCN 1154 is being developed as a convenient at-home treatment for rapid relief of postpartum depression, potentially serving as a first-line treatment option for women with PPD [4]. - The product is particularly beneficial for patients with severe PPD, including those at elevated suicide risk, where rapid improvement is critical [4]. Group 3: Market Context and Unmet Needs - Postpartum depression is a significant mental health issue affecting 20-40% of obstetric patients, with current treatment options limited by delayed onset and tolerability concerns [5]. - Traditional antidepressants, not specifically approved for PPD, have slow onset and side effects, highlighting the need for effective treatments like LPCN 1154 [5]. Group 4: Company Overview - Lipocine is a biopharmaceutical company focused on developing innovative products with effective oral delivery, targeting large markets with significant unmet medical needs [6]. - The company's development pipeline includes various candidates for mental health and other conditions, with LPCN 1154 being a key focus for postpartum depression [7].

Core Viewpoint - Lipocine Inc. has completed a scheduled independent Data Safety Monitoring Board (DSMB) review of its Phase 3 clinical trial for LPCN 1154, which is aimed at treating postpartum depression (PPD), and the trial will continue without modifications [1][2]. Group 1: Clinical Trial Details - The DSMB's recommendation was based on safety data from 82 randomized participants, with 74 completing dosing, and no serious adverse events or treatment discontinuations reported [2][7]. - The study is no longer screening new participants but continues to enroll eligible participants, with topline safety and efficacy results expected in early Q2 2026 [3][4]. - The Phase 3 study is a pivotal, randomized, double-blind trial comparing LPCN 1154 to placebo in women aged 15 and older diagnosed with severe PPD, conducted entirely in an outpatient setting [4][5]. Group 2: Product Overview - LPCN 1154 is an oral formulation of brexanolone designed for rapid relief of PPD, potentially becoming a first-line treatment option for women, with no significant risk of adverse reactions to breastfed infants [5][6]. - The product aims to address the unmet medical needs in PPD treatment, as traditional antidepressants have slow onset and side effects [6]. Group 3: Company Background - Lipocine is a biopharmaceutical company focused on developing innovative products with effective oral delivery, targeting large markets with significant unmet medical needs [8][9]. - The company's development pipeline includes several candidates for various conditions, including LPCN 2201 for major depressive disorder and LPCN 2101 for epilepsy, among others [9].

Core Viewpoint - Lipocine Inc. is progressing in its Phase 3 clinical trial for LPCN 1154, an oral treatment for postpartum depression (PPD), with 80% enrollment completed and positive recommendations from the Data Safety Monitoring Board [1][2][7] Company Overview - Lipocine Inc. is a biopharmaceutical company focused on developing innovative products with effective oral delivery using its proprietary technology platform [5] - The company has multiple drug candidates in development targeting significant unmet medical needs, including LPCN 1154 for PPD and others for major depressive disorder, epilepsy, and obesity management [6] Phase 3 Study Details - The Phase 3 study is a pivotal, randomized, double-blind trial comparing LPCN 1154 to placebo in women aged 15 and older diagnosed with severe PPD [2] - The trial is conducted entirely in an outpatient setting, following feedback from the U.S. FDA, and does not require medical monitoring by healthcare providers [2] - Data from this trial is expected to support a 505(b)(2) NDA submission for LPCN 1154 in 2026 [2] LPCN 1154 Characteristics - LPCN 1154 is an oral formulation of brexanolone aimed at providing rapid relief for PPD, potentially becoming a first-line treatment option [3] - The formulation is designed to minimize risks for breastfeeding infants while addressing acute needs in patients with elevated suicide risk [3] Postpartum Depression Context - PPD is a major depressive disorder that can occur during pregnancy or within four weeks post-delivery, with symptoms including sadness, fatigue, and suicidal thoughts [4] - A survey indicated that obstetricians estimate 20-40% of their patients may suffer from PPD, highlighting a significant unmet medical need in this population [4]

Core Insights - The Drug Safety Monitoring Board (DSMB) has reviewed the ongoing Phase 3 clinical trial of LPCN 1154 and has recommended that the study continue as planned [1] - More than half of the planned participants have completed dosing without any reported dose reductions, discontinuations, drug-related serious adverse events (SAEs), loss of consciousness, or excessive sedation [1] - Topline results are expected to be available in the second quarter of 2026 [1] Company Summary - Lipocine Inc. is a biopharmaceutical company focused on developing innovative products with effective oral delivery using its proprietary technology platform [1] - The ongoing Phase 3 clinical trial is evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of postpartum depression (PPD) [1] - The DSMB review was conducted after approximately one-third of the planned 80 participants (n=30) completed at least the day seven follow-up visit [1]

Core Insights - Lipocine (LPCN) reported a quarterly loss of $0.59 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.56, and compared to a loss of $0.44 per share a year ago, indicating a negative earnings surprise of -5.36% [1] - The company generated revenues of $0.12 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 15.00%, a significant improvement from zero revenues a year ago [2] - Lipocine's stock has declined approximately 47.5% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Company Performance - Over the last four quarters, Lipocine has consistently failed to meet consensus EPS estimates [2] - The current consensus EPS estimate for the upcoming quarter is -$0.55 on revenues of $0.1 million, while for the current fiscal year, it is -$1.87 on revenues of $0.92 million [7] - The estimate revisions trend for Lipocine was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Lipocine belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]